Updated 6/28/2024. The results chart includes audits where the findings have been finalized. Remaining audits are still under review. Information on Corrective Action Plans and Sanctions will be updated once approved by HRSA. HRSA recommends covered entities do not contact audited manufacturers regarding sanctions until a corrective action plan has been approved by HRSA and posted on this website.
| Manufacturer Sort descending | Labeler Codes Reviewed | State | OPA Findings | Sanction | Corrective Action Status |
|---|---|---|---|---|---|
| Amryt Pharmaceuticals, Inc. |
10122 69880 76431 |
NC |
No adverse findings |
None |
N/A Audit closure date: May 14, 2024 |
| Ascend Laboratories, LLC |
53097 67877 |
NJ |
No adverse findings |
None |
N/A Audit closure date: May 2, 2024 |
| Asegua Therapeutics, LLC |
15584 55135 61958 71287 72626 |
CA |
No adverse findings |
None |
N/A Audit closure date: May 15, 2024 |
| B. Braun Medical, Inc. | 264 | PA |
B. Braun charged more than the 340B ceiling price. B. Braun did not determine the difference between new drug price estimates and actual 340B ceiling price and offer a refund. |
Repayment to covered entities |
Pending |